SEC Filings
Form 10-Q
COLLEGIUM PHARMACEUTICAL, INC filed this Form 10-Q on 05/09/2018
Document Outline
Entire Document (5128.6 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - FORWARD-LOOKING STATEMENTS
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - Collegium Pharmaceutical, Inc.
Page 6 - Collegium Pharmaceutical, Inc.
Page 7 - Collegium Pharmaceutical, Inc.
Page 8 - Significant Accounting Policies
Page 9 - Advertising and Product Promotion Costs
Page 10 - Classification of Certain Cash Receipts and Cash PaymentsRestricted Cash
Page 11 - Adoption of ASC Topic 606, Revenue from Contracts with Customers
Page 12 - Disaggregation of Revenue
Page 13 - 5. Fair Value of Financial Instruments
Page 14 - 6. Inventory
Page 15 - Nucynta Asset Acquisition Obligations
Page 16 - Amortization Expense
Page 17 - 10. Equity
Page 18 - Restricted Stock Awards, Restricted Stock Units and Stock Options
Page 19 - Employee Stock Purchase Plan
Page 20 - Nucynta Litigation
Page 21 - Orange Book
Page 22 - Outlook
Page 23 - CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
Page 24 - RESULTS OF OPERATIONS
Page 25 - LIQUIDITY AND CAPITAL RESOURCES
Page 26 - Cash Flows
Page 27 - CONTRACTUAL OBLIGATIONS
Page 28 - Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Page 29 - PART II OTHER INFORMATION
Page 30 - If we require additional capital to fund our operations and we fail to obtain necessary financing, w
Page 31 - N/A
Page 32 - Raising additional capital may cause dilution to our existing shareholders, restrict our operations
Page 33 - Our ability to use our net operating loss carryforwards and certain other tax attributes may be limi
Page 34 - We have been and may be the subject of litigation matters, including government investigations, for
Page 35 - Risks Related to our Products and Product Candidates
Page 36 - Despite receiving approval by the FDA, additional data may emerge that could change the FDA s positi
Page 37 - Our decision to seek approval of our product candidates under Section 505(b)(2) increases the risk t
Page 38 - N/A
Page 39 - Development of our product candidates is not complete, and we cannot be certain that our product can
Page 40 - If we fail to comply with our obligations in the agreements under which we license intellectual prop
Page 41 - If we fail to obtain the necessary final regulatory approvals, or if such approvals are limited, we
Page 42 - Even if our product candidates receive regulatory approval, they will be subject to ongoing regulato
Page 43 - Failure to comply with ongoing governmental regulations for marketing any product, including Xtampza
Page 44 - Xtampza, the Nucynta Products and our product candidates contain controlled substances, the manufact
Page 45 - Clinical development is a lengthy and expensive process with an uncertain outcome, and failure can o
Page 46 - Because the results of preclinical studies and early-stage clinical trials are not necessarily predi
Page 47 - Xtampza, the Nucynta Products, and our product candidates may be associated with undesirable adverse
Page 48 - If we are unable to obtain or maintain intellectual property rights for our technology, products and
Page 49 - The patent prosecution process is expensive and time-consuming, and we may not be able to file and p
Page 50 - We may be forced to litigate to enforce or defend our intellectual property, which could be expensiv
Page 51 - If we are unable to protect the confidentiality of our trade secrets, our business and competitive p
Page 52 - Risks Related to the Commercialization of Our Products and Product Candidates
Page 53 - Recently enacted and future legislation may increase the difficulty and cost for us to commercialize
Page 54 - N/A
Page 55 - Even if we are able to commercialize our products and any of our product candidates, if approved, ou
Page 56 - N/A
Page 57 - If the FDA or other applicable regulatory authorities approve generic products with abuse deterrent
Page 58 - N/A
Page 59 - Because we currently rely on a sole supplier to manufacture the active pharmaceutical ingredient of
Page 60 - In the future, we may depend on collaborations with third parties for the development and commercial
Page 61 - We may rely on collaborators to market and commercialize our products, and, if approved, our product
Page 62 - Risks Related to Our Business and Strategy
Page 63 - Our future success depends on our ability to retain our key personnel.
Page 64 - We may acquire other assets or businesses, or form collaborations or make investments in other compa
Page 65 - Our relationships with customers and payors are subject to applicable anti-kickback, fraud and abuse
Page 66 - N/A
Page 67 - If we fail to comply with environmental, health and safety laws and regulations, we could become sub
Page 68 - N/A
Page 69 - Sales of a substantial number of shares of our common stock in the public market could cause our sto
Page 70 - Our principal shareholders and management own a significant portion of our stock and have the abilit
Page 71 - N/A
Page 72 - We may fail to qualify for continued listing on The NASDAQ Global Select Market which could make it
Page 73 - If we fail to maintain an effective system of internal control over financial reporting, we may not
Page 74 - The exercise of options and warrants and other issuances of shares of common stock or securities con
Page 75 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Page 76 - Item 6. Exhibits.
Page 77 - SIGNATURES
Subdocument 2 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - TABLE OF CONTENTS
Page 3 - EXHIBIT
Page 4 - LEASE
Page 5 - N/A
Page 6 - N/A
Page 7 - ARTICLE II
Page 8 - N/A
Page 9 - Valuation Expert
Page 10 - Right of First RefusalRight of First Refusal Space
Page 11 - First Offer NoticeTenant's ROFO Notice
Page 12 - Fourth Floor First Offer NoticeTenant's Fourth Floor ROFO Notice
Page 13 - ARTICLE III
Page 14 - Lab AreaExhibit CExhibit CLandlord's WorkExhibit BAdditional Allowance
Page 15 - Excess Costs
Page 16 - ARTICLE IV
Page 17 - Operating Expenses
Page 18 - Management Fee
Page 19 - Utility CostsSubmeter
Page 20 - N/A
Page 21 - ARTICLE V
Page 22 - Business Interruption Insurance
Page 23 - N/A
Page 24 - Definition of "Hazardous Material
Page 25 - Landlord's Rights
Page 26 - Exhibit C-2
Page 27 - ARTICLE VI
Page 28 - Exhibit E
Page 29 - N/A
Page 30 - ARTICLE VII
Page 31 - ARTICLE VIII
Page 32 - Permitted Transferee
Page 33 - ARTICLE IX
Page 34 - N/A
Page 35 - ARTICLE X
Page 36 - N/A
Page 37 - ARTICLE XI
Page 38 - N/A
Page 39 - N/A
Page 40 - USA Patriot Act
Page 41 - Exhibit G.Exhibit G
Page 42 - N/A
Page 43 - EXHIBIT A
Page 44 - EXHIBIT B
Page 45 - N/A
Page 46 - N/A
Page 47 - EXHIBIT B-1
Page 48 - EXHIBIT C
Page 49 - EXHIBIT C-1
Page 50 - EXHIBIT C -1 Landlord s Work
Page 51 - General
Page 52 - 1. Interior Partitions
Page 53 - 4. Ceilings
Page 54 - 7. Painting
Page 55 - 10. Electrical
Page 56 - 11. Fire Protection
Page 57 - 14. GENERAL NOTES
Page 58 - 15. TENANT SPECIFIC IT EQUIPMENT ROOM
Page 59 - EXHIBIT C-2
Page 60 - EXHIBIT D
Page 61 - N/A
Page 62 - EXHIBIT E
Page 63 - D. Miscellaneous Services
Page 64 - EXHIBIT F
Page 65 - provided, however,
Page 66 - N/A
Page 67 - N/A
Page 68 - N/A
Page 69 - COMMONWEALTH OF MASSACHUSETTS
Page 70 - N/A
Page 71 - COMMONWEALTH OF MASSACHUSETTS
Page 72 - EXHIBIT G
Page 73 - N/A
Page 74 - N/A
Page 75 - Attachment 1
Page 76 - Attachment 2
Page 77 - SCHEDULE 1
Page 78 - N/A
Subdocument 3 - EX-10.3 - EX-10.3
Page 1 - Exhibit 10.3
Page 2 - Signing BonusSigning Bonus
Page 3 - TerminationSection 5
Page 4 - Sections 5.1.2 and 5.1.3
Page 5 - provided that
Page 6 - Section 6Restrictive Covenants
Page 7 - Property of the Company
Page 8 - Definitions
Page 9 - Remedies and Enforcement Upon Breach
Page 10 - Severability
Page 11 - Signature Page to Employment Agreement
Subdocument 4 - EX-10.5 - EX-10.5
Page 1 - Exhibit 10.5
Page 2 - 3. Limitation of Amendment.
Page 3 - 5. Updated Schedule D. Updated Schedule D
Page 4 - IN WITNESS WHEREOF,
Page 5 - EXHIBIT 1
Page 6 - SCHEDULE D
Page 7 - Exhibit ASchedule D
Page 8 - EXHIBIT A TO SCHEDULE D
Page 9 - N/A
Page 10 - N/A
Subdocument 5 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 6 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 7 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 8 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer